All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | MAR 2025 | MAR 2024 | MAR 2023 ~1.5:1 split | MAR 2022 ~1.4:1 split |
|---|---|---|---|---|---|
| Operating Expenses | |||||
| Selling & Marketing | – | $0 | – | – | – |
| General & Administrative | – | $1 | $1 | $0 | $0 |
| Research & Development | – | $1 | $2 | – | – |
| Total Operating Expenses | – | $2 | $3 | $0 | $0 |
| Operating Income | – | -$2 | -$3 | -$0 | -$0 |
| Non-Operating | |||||
| Net Interest Expense | – | -$0 | -$0 | -$0 | -$0 |
| Other Non-Operating Income (Expense) | – | -$1 | -$0 | -$0 | -$0 |
| Income Tax Expense | – | -$0 | – | – | – |
| Earnings from Continuing Ops | – | – | – | -$0 | -$0 |
| Net Income | |||||
| Net Income | – | -$3 | -$4 | -$0 | -$0 |
| EPS (Basic) | – | – | -$0.01 | -$0.00 | -$0.00 |
| EPS (Diluted) | – | – | -$0.01 | -$0.00 | -$0.00 |
| Weighted Avg Shares (Basic) | 281.6M | 278.7M | 277.7M | 277.1M | 183.4M |
| Weighted Avg Shares (Diluted) | – | – | – | – | 183.4M |
| Shares Outstanding | 282.8M | 281.1M | 278.2M | 277.1M | 183.4M |
SourceFinancial statements computed from the 10-Q filed 17 Nov 2025, covering the period ending 30 Sept 2025, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with RGPX
Spot a number that looks wrong? Check it in RGPX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RGPX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.